Glizihenz-M-80 Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, enhances pancreatic insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and increases peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The synergistic action of these two agents addresses multiple pathophysiological defects in type 2 diabetes, facilitating better blood glucose regulation. Glizihenz-M-80 is recommended as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, particularly due to the sulfonylurea component. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis associated with Metformin use. Patient education on adherence, diet, and symptom recognition is crucial for optimal therapeutic outcomes. Glizihenz-M-80 should be prescribed under medical supervision with periodic assessment of renal function and glycemic status.